ArticleBiotechnology and applied biochemistry2026
A New Strategy of Alternating Current Magnetic Field-Assisted Three-Phase Partitioning (ACMF-TPP) for the Concentration and Partial Purification of Recombinant Prepromelittin Produced by Komagataella phaffii.
Article in Biotechnology and applied biochemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The industrial-scale manufacturing and purification of melittin are of great interest due to its significant antibacterial and anticancer properties. Here, for the first time, prepromelittin (ppMEL), the precursor of melittin-a key component of bee venom-was extracellularly produced by Komagataella phaffii, and an alternating current magnetic field-assisted three-phase partitioning (ACMF-TPP) method was used to concentrate and partially purify the recombinant ppMEL (rppMEL). ACMF-TPP, a novel variation of the traditional TPP method widely used for biomolecular purification, was employed to purify recombinant protein from culture liquid more rapidly and in larger quantities. First, the amplified ppMEL gene was inserted into pPICZαA. So, the obtained pPICZαA-ppMEL was cloned into E. coli. Then, K. phaffii cells were transformed with linearized recombinant DNA, and a yeast clone was cultivated for extracellular rppMEL production. The optimal conditions of ACMF-TPP for the purification and concentration of rppMEL were the following parameters: pH 6.7, 70% w/v ammonium sulfate concentration, a 1:1 ratio of culture liquid to 2-propanol, 100% power, a 10-minute magnetic field duration, and a 70% duty cycle. As a result, it was observed that rppMEL primarily precipitated at the interface and that the difference in recovery efficiency (32.5% for TPP and 66.1% for ACMF-TPP, respectively) was statistically significant. The ACMF-TPP approach exhibited more efficacy than the TPP, demonstrating superior potential for separating and purifying other biomolecules. Moreover, this approach offers a cost-effective and scalable solution for the precise isolation, purification, and concentration of mixture components.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.